Even as numerous gene therapies clear regulatory hurdles, one obstacle continues to cast a shadow over progress: delivery. Here we present our non-viral delivery report that identifies top-40 emerging early-stage companies and covers the current landscape, including the various modalities under development.
AAV remains the vector of choice in most in vivo gene therapy applications, used in >80% of the >2,000 gene therapies currently under development.
LNPs dominate the non-viral delivery segment, piggybacking on the successful use of such technologies by Moderna and Pfizer/BioNTech during the coronavirus pandemic.
Phase III studies by Intellia Therapeutics of liver-targeting mRNA-LNPs have commenced, cementing the company’s position as the leading player in the non-viral gene editing space.
Ex-liver delivery remains a core challenge for in vivo applications of mRNA-LNPs — only one non-liver tissue, lung, has observed clinical advancements (Arcturus Therapeutics & ReCode Therapeutics — Phase I for CF).
Non-viral vectors are evolving beyond lipid- and polymer-based systems, with key opinion leaders backing virus-like particles (VLPs) as a modality with significant potential.
Non-viral delivery companies strike large biopharma deals, as evidenced by GenEdit’s recent $644M deal with Genentech to develop polymer nanoparticles for autoimmune indications.
VC activity remains high, with top biotech investors participating in large financing rounds of Capstan Therapeutics ($175m series B — LNPs) and Nvelop Therapeutics ($100M seed — VLPs).
Significant academic breakthroughs were made in 2023, including the first reports of efficient delivery to photoreceptors and hematopoietic stem cells by LNPs in vivo.
Press enter or click to view image in full size
DALL·E 3: Lipid nanoparticle delivering RNA to a cell.
